Patients ≥65 years old with glioblastoma, IDH1/2-mutant astrocytoma, or oligodendroglioma had lower median survival compared to patients between 40–64 years and 20–39 years (all P ≤ .02, Figure 5A-C). This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).